Comparative Study of the TOMEY Specular Microscope EM-4000 and the Konan CellChek XL
Launched by TOMEY CORPORATION · Nov 28, 2016
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
The Tomey EM-4000 Specular Microscope is designed to observe and analyze corneal endothelium by capturing an image of corneal endothelium tissues. without making contact, analyzing the captured image, and calculating data such as cell density.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria-Non-pathologic young adults (18-28 years old) and non-pathologic adults (29-80 years old)
- • 1. Male or female subjects from 18 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed;
- • 2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
- • 3. Subjects who agree to participate in the study.
- Inclusion Criteria -Pathologic adults (29-80 years old):
- • 1. Male and female subjects from 29 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed;
- • 2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
- • 3. Subjects who agree to participate in the study;
- 4. At least one eye with any of the following conditions:
- • 1. History of post-op surgical trauma including pseudophakic or aphakic bullous keratopathy
- • 2. History of corneal transplant
- • 3. Physical injury or trauma to the cornea
- • 4. Fuch's dystrophy, Guttata or other corneal endothelial dystrophies
- • 5. Keratoconus
- • 6. Long-term polymethyl methacrylate (PMMA) contact lens use (greater than 3 years).
- • Exclusion Criteria - Non-pathologic young adults (18-28 years old) and non-pathologic adults (29-80 years old)
- • 1. History of post-op surgical trauma including bullous keratopathy;
- • 2. History of corneal transplant;
- • 3. Evidence of physical injury or trauma to the cornea;
- • 4. Fuch's dystrophy, Guttata or other corneal endothelial dystrophies;
- • 5. Keratoconus;
- • 6. Long-term PMMA contact lens use (greater than 3 years);
- • 7. History of cataract, refractive or ocular surgical procedures that render the cornea opaque or otherwise impact its ability to be imaged using the investigational device;
- • 8. Fixation problems which may prevent obtaining good Tomey EM-4000 and Konan CellChek XL images in either eye.
- • Exclusion Criteria - Pathologic adults (29-80 years old)
- • 1. History of cataract, refractive or ocular surgical procedures that render the cornea opaque or otherwise impact its ability to be imaged using the investigational device;
- • 2. Fixation problems which may prevent obtaining at least poor quality Tomey EM-4000 and Konan CellChek XL images in either eye.
About Tomey Corporation
Tomey Corporation is a leading innovator in the field of ophthalmic medical technology, dedicated to enhancing the quality of eye care through advanced diagnostic and therapeutic solutions. With a strong commitment to research and development, Tomey specializes in the design and manufacture of state-of-the-art instruments for optometry and ophthalmology, including devices for corneal topography, biometrics, and laser treatment. As a clinical trial sponsor, Tomey Corporation seeks to advance the understanding and treatment of ocular conditions, collaborating with healthcare professionals and institutions to bring cutting-edge therapies to market that improve patient outcomes and promote vision health globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials